{
    "clinical_study": {
        "@rank": "90858", 
        "arm_group": [
            {
                "arm_group_label": "Arm A: Sym004", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Arm B: Sym004", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Arm C: Investigator's choice", 
                "arm_group_type": "Active Comparator", 
                "description": "Best supportive care (BSC) or Fluorouracil (5-FU) or Capecitabine will be given as per Investigator's discretion."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a Phase 2, open-label, 3-arm trial of two Sym004 doses (Arms A and B) and a control\n      group (Arm C) in subjects with metastatic colorectal cancer (mCRC) and acquired resistance\n      to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs)."
        }, 
        "brief_title": "Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer", 
        "completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Metastatic Colorectal Cancer", 
        "condition_browse": {
            "mesh_term": "Colorectal Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Written informed consent obtained before undergoing any study-related activities\n\n          -  Male or female, at least 18 years of age\n\n          -  Subjects with histologically or cytologically confirmed mCRC, Kirsten rat sarcoma\n             wild-type (KRAS WT) at initial diagnosis\n\n          -  Failure of or intolerance to 5-FU, Oxaliplatin, and Irinotecan\n\n          -  Acquired resistance to marketed anti-EGFR mAbs as defined in the protocol\n\n          -  Measurable disease defined as one or more target lesions according to RECIST\n\n          -  Life expectancy of at least 3 months\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 1\n\n          -  Other protocol defined inclusion criteria could apply\n\n        Exclusion Criteria:\n\n          -  Pretreatment with regorafenib.\n\n          -  Subjects who in the opinion of the subject and investigator would  benefit  more\n             from  regorafenib  treatment  (except where regorafenib is not reimbursed in the\n             country)\n\n          -  Skin rash Common Terminology Criteria for AEs (CTCAE) Grade greater than 1 from\n             previous anti-EGFR therapy at time of randomization\n\n          -  Magnesium less than 0.9 milligram per deciliter (mg/dL)\n\n          -  Known hypersensitivity to any of the treatment ingredients. Known previous Grade 3-4\n             infusion related reactions with anti-EGFR mABs\n\n          -  Other protocol defined exclusion criteria could apply"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "240", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02083653", 
            "org_study_id": "EMR200637-002", 
            "secondary_id": "2013-003829-29"
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm A: Sym004", 
                "description": "Sym004 will be administered as an intravenous infusion at a dose of 12 milligram per kilogram (mg/kg) weekly until unacceptable toxicity, disease progression, or consent withdrawal.", 
                "intervention_name": "Sym004", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm B: Sym004", 
                "description": "Sym004 will be administered as an intravenous infusion at a loading dose of 9 mg/kg followed by 6 mg/kg weekly until unacceptable toxicity, disease progression, or consent withdrawal.", 
                "intervention_name": "Sym004", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm C: Investigator's choice", 
                "description": "BSC will be provided at the Investigator's discretion and may include antibiotics, analgesics, antiemetics, blood transfusions and nutritional support.", 
                "intervention_name": "Best supportive care (BSC)", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Arm C: Investigator's choice", 
                "description": "5-FU will be administered at doses and schedules as per Investigator's discretion and in line with the local package insert.", 
                "intervention_name": "Fluorouracil (5-FU)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm C: Investigator's choice", 
                "description": "Capecitabine will be administered at doses and schedules as per Investigator's discretion and in line with the local package insert.", 
                "intervention_name": "Capecitabine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antibodies, Monoclonal", 
                "Fluorouracil", 
                "Capecitabine", 
                "Cetuximab"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Metastatic Colorectal Cancer", 
            "Sym004", 
            "Best Supportive Care", 
            "Capecitabine", 
            "Fluorouracil (5-FU)"
        ], 
        "lastchanged_date": "March 7, 2014", 
        "location": [
            {
                "contact": {
                    "phone": "888-275-7376"
                }, 
                "facility": {
                    "address": {
                        "city": "Rockland", 
                        "country": "United States", 
                        "state": "Massachusetts"
                    }, 
                    "name": "Please Contact U.S. Medical Information"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "service@merckgroup.com", 
                    "phone": "+49 6151 72 5200"
                }, 
                "facility": {
                    "address": {
                        "city": "Darmstadt", 
                        "country": "Germany"
                    }, 
                    "name": "Please contact the Merck KGaA Communication Center"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Germany"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "Open-label, Randomized, Controlled, Multicenter Phase II Trial Investigating 2 Sym004 Doses Versus Investigator`s Choice (Best Supportive Care, Capecitabine, 5-FU) in Subjects With Metastatic Colorectal Cancer and Acquired Resistance to Anti-EGFR Monoclonal Antibodies", 
        "overall_contact": {
            "last_name": "US Medical Information", 
            "phone": "888-275-7376"
        }, 
        "overall_contact_backup": {
            "email": "service@merckgroup.com", 
            "last_name": "Merck KGaA Communication Center", 
            "phone": "+49 6151 72 5200"
        }, 
        "overall_official": {
            "affiliation": "Merck KGaA", 
            "last_name": "Medical Responsible", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Austria : Federal Ministry for Labour, Health, and Social Affairs", 
                "Austria: Agency for Health and Food Safety", 
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "Germany: Paul-Ehrlich-Institut", 
                "Hungary: National Institute for Quality and Organizational Development in Healthcare and Medicines", 
                "Italy: The Italian Medicines Agency", 
                "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products", 
                "Russia: FSI Scientific Center of Expertise of Medical Application", 
                "Russia: Ministry of Health of the Russian Federation", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "OS time is defined as the time from randomization to the date of death, assessed up to 2.5 years.", 
            "measure": "Overall survival (OS) Time", 
            "safety_issue": "No", 
            "time_frame": "Up to 2.5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02083653"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Best overall response according to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST v1.1)", 
                "safety_issue": "No", 
                "time_frame": "From randomization until first radiological confirmed or clinical progression event or death due to any cause within 12 weeks after last tumor assessment, assessed up to 2.5 years"
            }, 
            {
                "measure": "Progression Free Survival (PFS) Time", 
                "safety_issue": "No", 
                "time_frame": "Time from randomization until first radiological confirmed or clinical progression event or death due to any cause within 12 weeks after last tumor assessment, assessed up to 2.5 years"
            }, 
            {
                "measure": "Time to treatment failure", 
                "safety_issue": "No", 
                "time_frame": "Time from randomization to treatment failure or last tumor assessment, assessed up to 2.5 years"
            }, 
            {
                "measure": "Relative dose intensity of Sym004", 
                "safety_issue": "No", 
                "time_frame": "From first dose of study drug until unacceptable toxicity, disease progression, or consent withdrawal, assessed up to 2.5 years"
            }, 
            {
                "measure": "Pharmacokinetic parameters: AUC (0-168 hours), t1/2, CL, Vd, Cmax, tmax and C(trough)", 
                "safety_issue": "No", 
                "time_frame": "Up to Year 2.5"
            }, 
            {
                "measure": "Host immune response: Number of subjects with anti-drug antibodies (ADAs)", 
                "safety_issue": "No", 
                "time_frame": "Up to Week 24"
            }, 
            {
                "measure": "Biomarkers level related to the Epidermal growth factor receptor (EGFR) pathway", 
                "safety_issue": "No", 
                "time_frame": "Screening (Within 14 days prior to Day 1)"
            }, 
            {
                "measure": "Quality of life assessed by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer 30 (EORTC QLQ-C30) (Version 3)", 
                "safety_issue": "No", 
                "time_frame": "Every 6 weeks up to 2.5 years"
            }, 
            {
                "measure": "Quality of life assessed by EORTC QLQ module for colorectal cancer (EORTC QLQ-CR29)", 
                "safety_issue": "No", 
                "time_frame": "Every 6 weeks up to 2.5 years"
            }, 
            {
                "measure": "Quality of life assessed by Functional Assessment of Cancer Therapy-Epidermal Growth Factor Receptor Inhibitor 18 (FACT-EGFR 18)", 
                "safety_issue": "No", 
                "time_frame": "Every 3 weeks up to 2.5 years"
            }, 
            {
                "measure": "Number of subjects with adverse events (AEs), serious AEs, treatment emergent AEs, AEs leading to death, and AEs with National Cancer Institute-Common Terminology Criteria for AEs (NCI\u2212CTCAE Version 4.03) Grade greater than or equal to 3", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline up to 28 days after the last dose administration or up to 21 months"
            }
        ], 
        "source": "EMD Serono", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "EMD Serono", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}